JMPWA
HRTX icon

JP Morgan Private Wealth Advisors’s Heron Therapeutics HRTX Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-57,353
Closed -$86.6K – 1663
2023
Q1 		$86.6K Sell
57,353
-3,137
-5% -$7.86K ﹤0.01% 1904
2022
Q4 		$151K Buy
60,490
+8,449
+16% +$27.2K ﹤0.01% 1856
2022
Q3 		$220K Buy
52,041
+7,487
+17% +$29.3K ﹤0.01% 1772
2022
Q2 		$124K Sell
44,554
-2,810
-6% -$11.3K ﹤0.01% 1866
2022
Q1 		$271K Sell
47,364
-2,088
-4% -$15.3K ﹤0.01% 1792
2021
Q4 		$451K Buy
49,452
+7,358
+17% +$75.1K ﹤0.01% 1590
2021
Q3 		$450K Buy
42,094
+5,375
+15% +$65.4K ﹤0.01% 1538
2021
Q2 		$570K Buy
36,719
+13,962
+61% +$222K ﹤0.01% 1429
2021
Q1 		$369K Buy
22,757
+6,907
+44% +$123K ﹤0.01% 1438
2020
Q4 		$335K Hold
15,850
– – ﹤0.01% 1458
2020
Q3 		$235K Buy
15,850
+1,313
+9% +$20.5K ﹤0.01% 1467
2020
Q2 		$214K Buy
+14,537
New +$239K ﹤0.01% 1439

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

JP Morgan Private Wealth Advisors's HRTX Position: Q2 2023 in Review

JP Morgan Private Wealth Advisors sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 57,353 shares — an estimated $86.6K sold.

JP Morgan Private Wealth Advisors first reported a position in HRTX in Q2 2020 and held it in 12 quarters. The position peaked at $570K in Q2 2021. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • JP Morgan Private Wealth Advisors reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • JP Morgan Private Wealth Advisors sold 57,353 Heron Therapeutics shares in Q2 2023, an estimated $86.6K.
  • JP Morgan Private Wealth Advisors first reported a position in Heron Therapeutics in Q2 2020 and held it in 12 quarters.
  • JP Morgan Private Wealth Advisors's Heron Therapeutics position peaked at $570K in Q2 2021.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q2 2023, filed 28 Jul 2023.